Last updated: February 19, 2026
Vinorelbine Tartrate is an anti-mitotic chemotherapy agent used primarily to treat non-small cell lung carcinoma and metastatic breast cancer. This medication is available through multiple suppliers globally, either as a generic or branded product. The supply chain includes active pharmaceutical ingredient (API) manufacturers, finished drug product producers, and distribution channels.
Major API Manufacturers
| Company |
Location |
Certification |
Production Capacity |
Notes |
| Zhejiang Hisun Pharmaceuticals |
China |
GMP, ISO 9001, ISO 14001 |
Estimated in the tons/year |
Produces API for global export |
| Jiangxi Holi Chemical Co. |
China |
GMP |
Limited, scaled to demand |
Focus on small-molecule APIs |
| Teva Pharmaceutical Industries |
Israel |
GMP, ISO 9001 |
Large-scale API manufacturing |
Supplies API for multiple formulations |
| Bayer AG |
Germany |
GMP, ISO 9001 |
Extensive capacity |
Has historically supplied branded versions |
| Liwhon International Ltd. |
India |
GMP |
Moderate, scaled to markets |
API primarily for domestic and Asian markets |
Finished Drug Product Suppliers
| Company |
Location |
Product Range |
Approvals |
Distribution |
| Pfizer |
United States |
Brand name: Navelbine |
FDA, EMA, other national agencies |
Global supply with extensive distribution networks |
| Novartis |
Switzerland |
Generic Vinorelbine formulations |
WHO-GMP, regional approvals |
Wide availability in developed markets |
| Accord Healthcare |
India |
Generic Vinorelbine Tartrate |
WHO-GMP, US FDA, EU EMA |
Focus on emerging markets |
| Sun Pharma |
India |
Generic formulations |
WHO-GMP, US FDA |
Markets in Asia, Africa, Latin America |
Distribution Channels and Procurement
- Pharmaceutical Wholesalers: Distribute to hospitals, clinics, and pharmacies globally. Key players include McKesson, Cardinal Health, and Medline.
- Direct Procurement: Large healthcare providers and government agencies may procure directly from manufacturers or authorized distributors.
- Regulatory Approvals: Suppliers must have approval from agencies like the FDA, EMA, or national regulators to export the drug.
Quality and Regulatory Certification
- API suppliers typically hold certifications such as GMP (Good Manufacturing Practice), ISO 9001, and ISO 14001.
- Finished product suppliers must have approval for specific formulations in each target market.
- Some suppliers also attain WHO prequalification, facilitating access in low- and middle-income countries.
Strategic Considerations
- Market Access: Larger suppliers like Pfizer and Novartis maintain extensive regulatory dossiers, easing market entry.
- Pricing: Generics from Indian and Chinese suppliers often provide cost savings relative to branded options.
- Supply Chain Risks: Dependence on Chinese and Indian API manufacturers presents geopolitical and logistical risks.
Key Takeaways
- Multiple API producers in China, India, Israel, and Germany supply Vinorelbine Tartrate.
- The finished drug is produced by both large multinational corporations and regional generic manufacturers.
- Suppliers generally hold GMP and ISO certifications, aligning with international standards.
- Distribution channels include global wholesalers, direct procurement, and regional manufacturers.
- Regulatory approval and quality certification vary, influencing supply chain reliability and market access.
FAQs
Q1: Who are the leading API manufacturers for Vinorelbine Tartrate?
A: Zhejiang Hisun Pharmaceuticals, Jiangxi Holi Chemical Co., Teva, Bayer, and Liwhon International.
Q2: Which companies produce the finished Vinorelbine Tartrate products?
A: Pfizer, Novartis, Accord Healthcare, and Sun Pharma.
Q3: Are there regional differences in suppliers?
A: Yes. Chinese and Indian manufacturers dominate the API supply, while multinational firms produce branded finished drugs.
Q4: What certifications are required for supplying Vinorelbine Tartrate?
A: GMP, ISO 9001, and country-specific approvals such as FDA or EMA registration.
Q5: How does market access differ between branded and generic sources?
A: Branded products from large companies typically have faster regulatory approval, whereas generics may face additional registration requirements but offer lower prices.
References
[1] European Medicines Agency. (2022). Navelbine (Vinorelbine). EMA.
[2] World Health Organization. (2019). Prequalification of Medicines Programme. WHO.
[3] U.S. Food and Drug Administration. (2023). Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
[4] Global Data. (2022). Pharmaceutical API Manufacturing Markets.
[5] Indian Pharmaceutical Alliance. (2021). API Production and Export Statistics. IPA.
